Showing results (131-140 of 168) with videos related to
Sort By:
Pageof 17
JACC. Cardiovascular Interventions|April 26, 2023
Periprocedural Complications With Balloon Pulmonary Angioplasty: Analysis of Global StudiesNishant Jain, Muhammad A Sheikh, Divyansh Bajaj, et al.Journal of Racial and Ethnic Health Disparities|August 5, 2025
Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and EthnicityHarrison W Farber, Murali M Chakinala, Anna R Hemnes, et al.Chest|April 30, 2018
Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY TrialKelly M Chin, Mardi Gomberg-Maitland, Richard N Channick, et al.European Journal of Heart Failure|January 12, 2019
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON studyMaurice Beghetti, Richard N Channick, Kelly M Chin, et al.Annals of the Rheumatic Diseases|May 21, 2013
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT studyJ Gerry Coghlan, Christopher P Denton, Ekkehard Grünig, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 17, 2020
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON studyOlivier Sitbon, Kelly M Chin, Richard N Channick, et al.ERJ Open Research|January 23, 2023
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertensionJ Gerry Coghlan, Sean Gaine, Richard Channick, et al.The European Respiratory Journal|February 20, 2025
A Long-Term Follow-Up Study of Sotatercept for Treatment of Pulmonary Arterial Hypertension: Interim Results of SOTERIAIoana R Preston, David Badesch, Hossein-Ardeschir Ghofrani, et al.Journal of Medical Genetics|December 20, 2003
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasiaR E Harrison, J A Flanagan, M Sankelo, et al.ERJ Open Research|September 24, 2025
Clinical validation of a machine-learned, point-of-care system to IDENTIFY pulmonary hypertensionDalton McLean, John Rommel, John A Steuter, et al.Pageof 17